| Domain | Key findings for NEDHSS | Suggested ontology terms / identifiers | Evidence |
|---|---|---|---|
| Identity / identifiers | Disease name: **Neurodevelopmental disorder with hypotonia and speech delay, with or without seizures**; acronym **NEDHSS**. Authoritative disease identifiers available include **OMIM #620455** and **MONDO:0957541**. Disease-level information is derived from aggregated rare-disease/genotype-phenotype resources and the founding primary study, not EHR-only evidence. | **Validated identifiers:** OMIM:620455; MONDO:0957541. **Suggested synonym(s):** EIF4A2-related neurodevelopmental disorder; EIF4A2-related NDD. | (pqac-00000006, pqac-00000015, pqac-00000017) |
| Causal gene / inheritance | Causal gene: **EIF4A2** (alias **DDX2B**), encoding eukaryotic translation initiation factor 4A2. Current understanding supports **predominantly de novo autosomal dominant** disease, with review-level evidence also noting **one individual with a homozygous variant**, so a possible **autosomal recessive** presentation remains uncertain. | **Validated gene:** EIF4A2 / ENSG00000156976. **Suggested inheritance terms:** HP:0000006 Autosomal dominant inheritance; HP:0000007 Autosomal recessive inheritance (uncertain/possible, not fully established). | (pqac-00000006, pqac-00000015, pqac-00000017) |
| Core phenotypes | Core clinical concept from disease name and review evidence: **hypotonia**, **speech delay/language impairment**, and **seizures in a subset**. Broader developmental impairment/intellectual disability is also implicated in the primary association literature summarized by secondary sources. | **Suggested HPO terms:** HP:0001252 Hypotonia; HP:0002463 Delayed speech and language development; HP:0001250 Seizure; HP:0001263 Global developmental delay; HP:0001249 Intellectual disability. | (pqac-00000006, pqac-00000016, pqac-00000017) |
| Mechanism / pathophysiology | EIF4A2 is a **DEAD-box RNA helicase** and part of the **translation-initiation machinery**; disease mechanism is currently understood at a high level as disruption of RNA helicase/translation-related neurodevelopmental processes. The 2024 review states that **missense and loss-of-function variants** are associated with NEDHSS, but disease-specific causal molecular cascades remain incompletely defined. | **Suggested GO terms:** GO:0003724 RNA helicase activity; GO:0006413 translational initiation; GO:0006412 translation; GO:0002181 cytoplasmic translation; GO:0003676 nucleic acid binding. **Suggested mechanism label:** disturbed post-transcriptional gene-expression control during neurodevelopment. | (pqac-00000006, pqac-00000017) |
| Anatomy / cell types | Primary system affected is the **nervous system/brain**; phenotype implies involvement of neural circuits supporting muscle tone, language, and seizure susceptibility. No disease-specific cell-type-resolved human dataset was identified in the retrieved evidence. | **Suggested UBERON terms:** UBERON:0001016 nervous system; UBERON:0000955 brain; UBERON:0002596 cerebral cortex. **Suggested CL terms:** CL:0000540 neuron; CL:0002319 neural cell; CL:0000127 astrocyte (supporting-cell hypothesis, not disease-specificly validated). | (pqac-00000006, pqac-00000017) |
| Diagnostics | Most informative disease-specific test category is **genetic testing**, especially exome/genome-based testing in individuals with unexplained developmental delay, hypotonia, and speech delay with/without seizures. Open Targets evidence links the disease to EIF4A2 through genetic evidence including variant databases; no disease-specific biochemical biomarker or imaging signature was identified in retrieved evidence. | **Suggested diagnostic approach terms:** trio WES/WGS; targeted reanalysis of NDD gene panels including EIF4A2. **Suggested HPO-driven indication terms:** HP:0001263, HP:0001252, HP:0002463, HP:0001250. | (pqac-00000015, pqac-00000016, pqac-00000017) |
| Management | No NEDHSS-specific therapy or interventional trial was identified. Current management is supportive: developmental therapies, speech-language therapy, physical/occupational therapy, neurologic monitoring, and standard seizure management when epilepsy is present. | **Suggested NCIT terms:** Speech Therapy; Physical Therapy; Occupational Therapy; Anticonvulsant Therapy; Genetic Counseling. | (pqac-00000016, pqac-00000017) |
| Major evidence gaps | Major unresolved areas include: true **prevalence/incidence**, penetrance/expressivity, disease-specific **variant catalog and genotype-phenotype correlations**, validated **functional mechanism**, **animal/model-system** evidence specific to NEDHSS, biomarkers, natural-history cohorts, treatment-response data, and environmental or gene-environment modifiers. | **Suggested evidence-gap tags:** epidemiology unavailable; no validated biomarker; no disease-specific clinical guidelines found; no relevant registered interventional trials found in retrieved searches. | (pqac-00000015, pqac-00000016, pqac-00000017) |


*Table: This compact table summarizes the current evidence base and ontology-ready annotations for NEDHSS, including identifiers, causal gene, phenotype concepts, mechanism, anatomy, diagnostics, management, and key knowledge gaps. It is useful for knowledge-base population where suggested ontology terms must be distinguished from validated disease-specific findings.*